Compare LFMD & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LFMD | CYBN |
|---|---|---|
| Founded | 1994 | 2019 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 330.5M | 280.9M |
| IPO Year | N/A | N/A |
| Metric | LFMD | CYBN |
|---|---|---|
| Price | $3.50 | $5.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | $10.22 | ★ $74.50 |
| AVG Volume (30 Days) | ★ 1.7M | 615.4K |
| Earning Date | 11-17-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $250,091,814.00 | N/A |
| Revenue This Year | $13.65 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 28.78 | N/A |
| 52 Week Low | $3.43 | $4.81 |
| 52 Week High | $15.84 | $10.80 |
| Indicator | LFMD | CYBN |
|---|---|---|
| Relative Strength Index (RSI) | 24.69 | 49.09 |
| Support Level | $3.43 | $5.50 |
| Resistance Level | $3.84 | $6.23 |
| Average True Range (ATR) | 0.28 | 0.33 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 5.18 | 63.12 |
LifeMD Inc is a direct-to-patient telehealth company that provides a smarter, cost-effective, and more convenient way of accessing comprehensive, virtual healthcare. Its telehealth platform seamlessly integrates a clinician-centric electronic medical record (EMR) system, proprietary algorithms for case-load balancing and scheduling, customer relationship management functionality, remote and in-home lab testing, and digital prescription capabilities, patient-provider audio/video interfacing, cloud pharmacy fulfillment, and more. In addition to telehealth offerings, the company sells nutritional supplements and other over-the-counter products. The company has two operating segments: Telehealth and WorkSimpli. The company generates the majority of its revenue from the Telehealth segment.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.